Blue Trust Inc’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Blue Trust Inc’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-53	Closed	-$2K	–	2806
2023 Q4	$2K	Sell	53 -27	-34%	-$1.52K	﹤0.01%	2247
2023 Q3	$3K	Hold	80	–	–	﹤0.01%	1787
2023 Q2	$3K	Sell	80 -8	-9%	-$330	﹤0.01%	1698
2023 Q1	$4K	Buy	88 +81	+1,157%	+$3.64K	﹤0.01%	1887
2022 Q4	$0	Sell	7 -17	-71%	-$1.1K	﹤0.01%	2533
2022 Q3	$2K	Buy	+24	New	+$1.78K	﹤0.01%	1855

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Blue Trust Inc's MRTX Position: Q1 2024 in Review

Blue Trust Inc sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 53 shares — an estimated $2K sold.

Blue Trust Inc first reported a position in MRTX in Q3 2022 and held it in 6 quarters. The position peaked at $4K in Q1 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Blue Trust Inc reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Blue Trust Inc sold 53 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2K.
Blue Trust Inc first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2022 and held it in 6 quarters.
Blue Trust Inc's Mirati Therapeutics, Inc. Common Stock position peaked at $4K in Q1 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Blue Trust Inc's 13F filing for Q1 2024, filed 1 May 2024.